Congressman Morgan Griffith, Chairman of the Subcommittee on Health, delivered an opening statement at a hearing titled “Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role in Advancing U.S. Drug Development” on July 15. The hearing focused on strategies to ensure the United States remains a global leader in biopharmaceutical research and development.
Griffith said, “Today’s hearing will examine ways to maintain American leadership in biomedical innovation.” He emphasized the importance of learning what is working, identifying areas for improvement, and ensuring that Congress supports the Food and Drug Administration (FDA) in serving patients and promoting innovation.
He highlighted recent initiatives such as FDA’s Operation Trialblazer, launched by the current administration as an effort to respond to growing global competition. “Operation Trialblazer provides a set of initiatives and reforms to modernize and accelerate medical product development, aiming to remove the unnecessary hurdles and ambiguity that sometimes hinder patient access to innovative treatments,” Griffith said.
Griffith also discussed user fee programs that have supported FDA operations for over three decades. He explained that these fees are paid by manufacturers submitting products for review rather than relying solely on taxpayer dollars. According to Griffith, “The predictability and performance goals established through the user fee agreements have helped reduce review times, improve communication between FDA and product developers, and provide greater standardization throughout the review process.” He noted that reauthorization offers Congress an opportunity not just to extend current policies but also to explore legislative changes aimed at streamlining regulatory processes.
As one of its core functions, the House Energy and Commerce Committee focuses on legislation concerning energy policy, health care issues—including pharmaceutical pricing—environmental protection measures, telecommunications regulation, consumer protection matters, broadband deployment initiatives, as well as being one of the oldest standing committees tracing its origins back to 1795 when it formed as the Committee on Commerce and Manufactures, according to the official website.
Griffith concluded his remarks by stating his eagerness “to look for ways that we can help ensure FDA can review drugs in a timely and predictable manner. Not only to expand patient access to innovative treatments but also encourage companies to invest, develop, and manufacture domestically.”